Dr Chris Mathes is Chief Commercial Officer at Metrion and has over 25 years of experience in the biopharmaceutical industry, with a strong background in preclinical CRO leadership, sales, and marketing. His scientific background, particularly in ion channel research and patch clamp technology, has brought a unique and valuable perspective to each role throughout his career, and continues to inform Metrion’s commercial strategy and global business development.

Chris has held senior executive positions at several leading organisations in the sector, including AnaBios, Icagen, Charles River (ChanTest), and Sophion Bioscience. Earlier in his career, he played a pivotal role in the development of early automated patch clamp systems, first at Axon Instruments and later at Sophion Bioscience. Notably, he contributed to the successful acquisition of ChanTest by Charles River in 2014 for over $50 million.

Chris holds a BSc in Biology from Stanford University, a PhD in Neuroscience from UCLA, and an MBA from Rutgers University. His post-doctoral research, focused on ion channels, was conducted at both Stanford University and the Max Planck Institute for Biophysical Chemistry in Göttingen, Germany. He is the author of 17 peer-reviewed publications.